Skip to content
OVERVIEW
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.

OVERVIEW

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte to Present at the Canaccord Genuity 38th Annual Growth Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 30, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the Canaccord Genuity 38th Annual Growth Conference on Thursday, August 9, 2018 at 11:30 a.m.
View HTML
Toggle Summary Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 30, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its public offering of 5,750,000 shares of common stock, including 750,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a price
View HTML

Events

Date Event Details
Summary Toggle Aug 9, 2018 11:30 AM EDT
Canaccord Genuity 38th Annual Growth Conference

Speaker

Bonnie H. Anderson
Chairman of the Board and Chief Executive Officer
Summary Toggle Jul 23, 2018 1:30 PM PDT
Veracyte Second Quarter 2018 Financial Results Webcast

Presentations

Title Documents

Veracyte Corporate Presentation, August 2018